JAK inhibitor

WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...

Newton, Massachusetts, USA, April 21, 2026 In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that...

Madison, New Jersey, U.S. | April 15, 2026 LEO Pharma has announced that the U.S. Food and Drug Administration...

Rahway, New Jersey, USA — February 25, 2026 The U.S. Food and Drug Administration (FDA) has approved NUMELVI™ (atinvicitinib...

NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...

NORTH CHICAGO, Illinois, October 13, 2025 – AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration...

OTTAWA, Canada, September 9, 2025 — Health Canada has granted approval to Bylvay™ (odevixibat) for the treatment of cholestatic...